Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYL-1402O vs Avastin in First-Line Stage IV nsNSCLC
NCT04633564Phase 3Completed
- Sponsor
- Mylan
- Start
- Jan 2017
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of MYL-1402O in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by Mylan. Primary endpoint: Overall Response Rate at 18 weeks. Started Jan 2017; status: completed.
02
Drugs
MYL-1402O
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT04633564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04633564.